Effect of Intravenous vitamin c in Patients with COVID-19

Evaluation of effectiveness? of Intravenous vitamin c in Patients with COVID-19 Referred to Imam ?Khomeini Hospital: a clinical trial ?

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200411047025N1

Enrollment

110

Registered

2020-04-14

Start date

2020-04-18

Completion date

Unknown

Last updated

2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

covid-19. COVID-19, virus identified

Interventions

Intervention 1: Intervention group: case group 55 patients treat with intravenous vitamin c 1.5 gram 4 times a day and Hydroxychloroquine ??400 mg in the ?first day and then 200 mg BID plus Atazan

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: At least 18 years old The case of definite or probable of covid-19

Exclusion criteria

Exclusion criteria: The patient with chronic renal failure or dialysis The patient withG6PD deficiency

Design outcomes

Primary

Measure	Time frame
Improvement of SPO2 (stands for peripheral capillary oxygen saturation). Timepoint: Daily, until 3-5 days or discharge. Method of measurement: pulse oximetry.	—

Secondary

Measure	Time frame
Fever subside. Timepoint: 4 times a day until 3-5 days or discharge. Method of measurement: termometer.;CRP. Timepoint: Every other day until discharge. Method of measurement: Laboratory test.;Respiratory rate. Timepoint: 4 times a day until 3-5 days or discharge. Method of measurement: physical examination.;Lymphocytosis. Timepoint: every other day until discharge. Method of measurement: laboratory test.;Creatinine. Timepoint: every other day until discharge. Method of measurement: Laboratory test.	—

Measure

Time frame

Fever subside. Timepoint: 4 times a day until 3-5 days or discharge. Method of measurement: termometer.;CRP. Timepoint: Every other day until discharge. Method of measurement: Laboratory test.;Respiratory rate. Timepoint: 4 times a day until 3-5 days or discharge. Method of measurement: physical examination.;Lymphocytosis. Timepoint: every other day until discharge. Method of measurement: laboratory test.;Creatinine. Timepoint: every other day until discharge. Method of measurement: Laboratory test.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFereshteh Ghiasvand

Tehran University of Medical Sciences

ghiasvand_62@yahoo.com009861192811

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 24, 2026